Literature DB >> 15603050

Status of antituberculosis drug resistance in Saudi Arabia 1979-98.

K K Abu-Amero1.   

Abstract

All published material on the prevalence of drug-resistant tuberculosis within Saudi Arabia over the period 1979-98 was reviewed. The prevalence of single-drug-resistant tuberculosis ranged from 3.4% to 41% for isoniazid, 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol. The prevalence of multidrug-resistant tuberculosis (defined by WHO as resistance to two or more first-line antituberculosis drugs) ranged from 1.5% to 44% in different regions. No strong conclusions could be drawn owing to variations in the populations studied, geographical origins, site of Mycobacterium tuberculosis isolation (pulmonary or extrapulmonary) and drug sensitivity testing. However, the need to develop a standardized national policy for surveillance of drug-resistant tuberculosis in Saudi Arabia is clear.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 15603050

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Authors:  Sahal Al-Hajoj; Bright Varghese; Mohammed M Shoukri; Ruba Al-Omari; Mais Al-Herbwai; Fahad Alrabiah; Abdulrahman A Alrajhi; Naila Abuljadayel; Sahar Al-Thawadi; Alimuddin Zumla; Matteo Zignol; Mario C Raviglione; Ziad Memish
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

2.  Burden of Multidrug Resistant Mycobacterium tuberculosis Among New Cases in Al-Madinah Al-Monawarah, Saudi Arabia.

Authors:  Mogahid M Elhassan; Hassan A Hemeg; Miskelyemen A Elmekki; Khalid A Turkistani; Ahmed A Abdul-Aziz
Journal:  Infect Disord Drug Targets       Date:  2017

3.  Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.

Authors:  Khalifa M Binkhamis; Mohammed A Bahatheg; Faisal A Altahan; Saleh S Alwakeel; Khalid A Almutairi; Abdullah F Alsaeed; Dalal A Alkadi; Hanan A Alshafai; Fahad M Almajid; Mazin A Barry
Journal:  Saudi Med J       Date:  2021-06       Impact factor: 1.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.